Maura Pugliatti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Maura Pugliatti has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Trond Riise
Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway
6 shared publications Giulio Rosati
Università di Sassari
5 shared publicationsStefano Sotgiu
Institute of Clinical Neurology|Faculty of Medicine|University of Sassari
4 shared publicationsG. Rosati
University of Sassari
3 shared publicationsM. Alessandra Sotgiu
Institute of Clinical Neurology|Faculty of Medicine|University of Sassari
3 shared publicationsPatrik Sobocki
3 shared publications
Latest Publications
- 21 March 2015
- Published by Springer Nature in Journal of Neurology
- Vol. 262 (5) , 1271-1277
Reduced duration of breastfeeding is associated with a higher risk of multiple sclerosis in both Italian and Norwegian adult males: the EnvIMS study
Breastfeeding for at least 4 months has been found to be associated with a reduced risk of immune-mediated diseases including multiple sclerosis (MS). Using data from a large multinational case–control study (EnvIMS), the association between MS and breastfeeding was investigated in two distinct populations. A questionnaire (EnvIMS-Q) which included a section on feeding during the first year of life was administered to MS cases and to age and sex frequency-matched controls from Italy and Norway. Logistic regression was used to estimate the odds ratio (ORs) and 95 % confidence intervals (95 % CIs) as a measure of the association between MS and exposure to prolonged breastfeeding (4 months or more, used as the reference category), vs. no breastfeeding or breastfeeding for less than 4 months (reduced exposure). Education, smoking habits, smoking in mother’s pregnancy, and other types of milk used in infant feeding were included as covariates. A total of 547 cases and 1039 controls in Italy, and 737 cases and 1335 controls in Norway were studied. The distribution of prolonged (reference) breastfeeding differed between the Norwegian (65.4 %) and the Italian (48.9 %) study participants. A significant association between MS and reduced/no exposure to breastfeeding was found overall for Italy (ORadj = 1.37; 95 % CI 1.09, 1.73), but not for Norway (ORadj = 1.14; 95 % CI 0.92, 1.40). However, only in men, significant associations were observed for both populations (ORItaly = 2.33; 95 % CI 1.50, 3.65, ORNorway = 2.13; 95 % CI 1.37, 3.30). Reduced exposure to breastfeeding in males was found to be associated with increased risk of MS in Italy and in Norway.
- 21 March 2015
- Published by Springer Nature in Journal of Neurology
- Vol. 262 (5) , 1271-1277
Reduced duration of breastfeeding is associated with a higher risk of multiple sclerosis in both Italian and Norwegian adult males: the EnvIMS study
Breastfeeding for at least 4 months has been found to be associated with a reduced risk of immune-mediated diseases including multiple sclerosis (MS). Using data from a large multinational case–control study (EnvIMS), the association between MS and breastfeeding was investigated in two distinct populations. A questionnaire (EnvIMS-Q) which included a section on feeding during the first year of life was administered to MS cases and to age and sex frequency-matched controls from Italy and Norway. Logistic regression was used to estimate the odds ratio (ORs) and 95 % confidence intervals (95 % CIs) as a measure of the association between MS and exposure to prolonged breastfeeding (4 months or more, used as the reference category), vs. no breastfeeding or breastfeeding for less than 4 months (reduced exposure). Education, smoking habits, smoking in mother’s pregnancy, and other types of milk used in infant feeding were included as covariates. A total of 547 cases and 1039 controls in Italy, and 737 cases and 1335 controls in Norway were studied. The distribution of prolonged (reference) breastfeeding differed between the Norwegian (65.4 %) and the Italian (48.9 %) study participants. A significant association between MS and reduced/no exposure to breastfeeding was found overall for Italy (ORadj = 1.37; 95 % CI 1.09, 1.73), but not for Norway (ORadj = 1.14; 95 % CI 0.92, 1.40). However, only in men, significant associations were observed for both populations (ORItaly = 2.33; 95 % CI 1.50, 3.65, ORNorway = 2.13; 95 % CI 1.37, 3.30). Reduced exposure to breastfeeding in males was found to be associated with increased risk of MS in Italy and in Norway.
- 20 October 2013
- Published by Springer Nature in Journal of Neurology
- Vol. 261 (1) , 52-59
The high prevalence of hereditary spastic paraplegia in Sardinia, insular Italy
The few epidemiological studies conducted to date on the heterogeneous group of hereditary spastic paraplegias (HSPs) indicate a prevalence of 1.27–12.1 per 100,000. This study aims to explore the epidemiological, clinical, and genetic variability of HSPs among Sardinians, a population of peculiar ethnicity.A population-based prevalence study was performed in north-western Sardinia between January 2000 and December 2010. Multiple sources were used for case ascertainment. Familial and sporadic cases were diagnosed according to generally accepted criteria, and clinical diagnoses were validated by expert neurological examination. Clinical data and pedigree information were recorded and blood samples drawn for genetic testing.Sixty-seven HSP patients were included in the study: 59 belonged to 11 families with autosomal dominant transmission (AD-HSP), three cases were from two unrelated autosomal recessive families, and the remaining five cases were apparently sporadic. On 31 December 2010, the total crude prevalence was 19.9 per 100,000 (95 % CI 18.4–21.4), while the crude prevalence of AD-HSP was 17.5 (24.4 M, 15.7 F; M:F ratio 1.55). The mean age at examination was 48.4 years, and the mean age at onset of HSP was 36.6 years. A molecular diagnosis was obtained in 82.1 % of the cases (52 cases with mutations in SPAST/SPG4, two in SPG7, and one in SPG11).The prevalence of HSP among Sardinians is high compared with other Western European populations. The multiple search strategy used in this study and the specific socio-demographic characteristics of Sardinians may account for this finding.
- 20 October 2013
- Published by Springer Nature in Journal of Neurology
- Vol. 261 (1) , 52-59
The high prevalence of hereditary spastic paraplegia in Sardinia, insular Italy
The few epidemiological studies conducted to date on the heterogeneous group of hereditary spastic paraplegias (HSPs) indicate a prevalence of 1.27–12.1 per 100,000. This study aims to explore the epidemiological, clinical, and genetic variability of HSPs among Sardinians, a population of peculiar ethnicity.A population-based prevalence study was performed in north-western Sardinia between January 2000 and December 2010. Multiple sources were used for case ascertainment. Familial and sporadic cases were diagnosed according to generally accepted criteria, and clinical diagnoses were validated by expert neurological examination. Clinical data and pedigree information were recorded and blood samples drawn for genetic testing.Sixty-seven HSP patients were included in the study: 59 belonged to 11 families with autosomal dominant transmission (AD-HSP), three cases were from two unrelated autosomal recessive families, and the remaining five cases were apparently sporadic. On 31 December 2010, the total crude prevalence was 19.9 per 100,000 (95 % CI 18.4–21.4), while the crude prevalence of AD-HSP was 17.5 (24.4 M, 15.7 F; M:F ratio 1.55). The mean age at examination was 48.4 years, and the mean age at onset of HSP was 36.6 years. A molecular diagnosis was obtained in 82.1 % of the cases (52 cases with mutations in SPAST/SPG4, two in SPG7, and one in SPG11).The prevalence of HSP among Sardinians is high compared with other Western European populations. The multiple search strategy used in this study and the specific socio-demographic characteristics of Sardinians may account for this finding.
- 19 February 2013
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 9 (3) , 129-130
Preventing progression and disability in MS—when to treat?
In relapsing–remitting multiple sclerosis, conversion to the progressive stage is thought to be influenced by early relapses. Despite a new study suggesting that relapses do not drive long-term disability and proposing the latency period as an ideal target for therapeutic intervention, the relapsing phase remains a relevant treatment window.
- 19 February 2013
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 9 (3) , 129-130
Preventing progression and disability in MS—when to treat?
In relapsing–remitting multiple sclerosis, conversion to the progressive stage is thought to be influenced by early relapses. Despite a new study suggesting that relapses do not drive long-term disability and proposing the latency period as an ideal target for therapeutic intervention, the relapsing phase remains a relevant treatment window.
- 20 December 2012
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 126 (195) , 43-50
A questionnaire for multinational case-control studies of environmental risk factors in multiple sclerosis (EnvIMS-Q)
Objectives The increasing incidence of multiple sclerosis (MS) worldwide, especially in women, points to the crucial role of environmental and lifestyle risk factors in determining the disease occurrence. An international multicentre case–control study of Environmental Risk Factors In Multiple Sclerosis (EnvIMS) has been launched in Norway, Sweden, Italy, Serbia and Canada, aimed to examine MS environmental risk factors in a large study population and disclose reciprocal interactions. To ensure equivalent methodology in detecting age‐related past exposures in individuals with and without MS across the study sites, a new questionnaire (EnvIMS‐Q) is presented. Materials and methods EnvIMS‐Q builds on previously developed guidelines for epidemiological studies in MS and is a 6‐page self‐administered postal questionnaire. Participants are de‐identified through the use of a numerical code. Its content is identical for cases and controls including ‘core’ and population‐specific questions as proxies for vitamin D exposure (sun exposure, dietary habits and supplementation), childhood infections (including infectious mononucleosis) and cigarette smoking. Information on possible confounders or effect modifiers is also obtained. EnvIMS‐Q was initially drafted in English and subsequently translated into Italian, Serbian, Norwegian, Swedish and French‐Canadian. EnvIMS‐Q has been tested for acceptability, feasibility and reliability. Results and Conclusions EnvIMS‐Q has shown cross‐cultural feasibility, acceptability and reliability in both patients with MS and healthy subjects from all sites. EnvIMS‐Q is an efficient tool to ensure proper assessment of age‐specific exposure to environmental factors in large multinational population‐based case–control studies of MS risk factors.
- 20 December 2012
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 126 (195) , 43-50
A questionnaire for multinational case-control studies of environmental risk factors in multiple sclerosis (EnvIMS-Q)
Objectives The increasing incidence of multiple sclerosis (MS) worldwide, especially in women, points to the crucial role of environmental and lifestyle risk factors in determining the disease occurrence. An international multicentre case–control study of Environmental Risk Factors In Multiple Sclerosis (EnvIMS) has been launched in Norway, Sweden, Italy, Serbia and Canada, aimed to examine MS environmental risk factors in a large study population and disclose reciprocal interactions. To ensure equivalent methodology in detecting age‐related past exposures in individuals with and without MS across the study sites, a new questionnaire (EnvIMS‐Q) is presented. Materials and methods EnvIMS‐Q builds on previously developed guidelines for epidemiological studies in MS and is a 6‐page self‐administered postal questionnaire. Participants are de‐identified through the use of a numerical code. Its content is identical for cases and controls including ‘core’ and population‐specific questions as proxies for vitamin D exposure (sun exposure, dietary habits and supplementation), childhood infections (including infectious mononucleosis) and cigarette smoking. Information on possible confounders or effect modifiers is also obtained. EnvIMS‐Q was initially drafted in English and subsequently translated into Italian, Serbian, Norwegian, Swedish and French‐Canadian. EnvIMS‐Q has been tested for acceptability, feasibility and reliability. Results and Conclusions EnvIMS‐Q has shown cross‐cultural feasibility, acceptability and reliability in both patients with MS and healthy subjects from all sites. EnvIMS‐Q is an efficient tool to ensure proper assessment of age‐specific exposure to environmental factors in large multinational population‐based case–control studies of MS risk factors.
- 30 September 2012
- Published by Springer Nature in Journal of Neurology
- Vol. 260 (2) , 572-579
Amyotrophic lateral sclerosis in Sardinia, insular Italy, 1995–2009
Recent genetic studies suggest a Sardinian type of amyotrophic lateral sclerosis (ALS). Thus, ALS incidence, prevalence and survival were investigated in a large population of Sardinians aimed to disclose population-specific patterns and their temporal changes. This is a population-based incidence and prevalence study in northern and central Sardinia, insular Italy (over 700,000 population). Incidence rates were computed for the time interval 1995–2009 and by quinquennia. Prevalence was computed for prevalence days 31 December 2004 and 2009. Onset-based survival for 1995–2009 is also reported. All ALS patients (El Escorial Criteria) in the study area were retrospectively included. The ALS crude incidence from 2005–2009 was 2.5 (95 % CIs: 0.1, 4.9), 3.4 in men and 1.6 in women. Onset occurred most often between the age of 65–74 years in men and 55–64 years in women. The ALS incidence tended to increase over the period 1995–2009. The mean age at onset was 61.7 years with no difference based on gender, varying significantly from 59.9 years in 1995–1999 to 63.9 years in 2005–2009. On December 31, 2009, the ALS crude prevalence was 10.8 per 100,000 (95 % CIs: 8.6, 13.1), 13.8 in men and 8.0 in women, whereas it was 6.3 per 100,000 (95 % CIs: 4.1, 8.6) on December 31, 2004 (M:F ratio of 0.95). Mean survival from onset was 37.0 months, with no difference based on gender, and a tendency to decrease during the period 1995–2009, in relation to type and age of onset. The population-based incidence and prevalence data of ALS in Sardinians indicate an increase of the disease occurrence over the past 40 years, providing support for a population-specific variant of ALS in Sardinia.
- 30 September 2012
- Published by Springer Nature in Journal of Neurology
- Vol. 260 (2) , 572-579
Amyotrophic lateral sclerosis in Sardinia, insular Italy, 1995–2009
Recent genetic studies suggest a Sardinian type of amyotrophic lateral sclerosis (ALS). Thus, ALS incidence, prevalence and survival were investigated in a large population of Sardinians aimed to disclose population-specific patterns and their temporal changes. This is a population-based incidence and prevalence study in northern and central Sardinia, insular Italy (over 700,000 population). Incidence rates were computed for the time interval 1995–2009 and by quinquennia. Prevalence was computed for prevalence days 31 December 2004 and 2009. Onset-based survival for 1995–2009 is also reported. All ALS patients (El Escorial Criteria) in the study area were retrospectively included. The ALS crude incidence from 2005–2009 was 2.5 (95 % CIs: 0.1, 4.9), 3.4 in men and 1.6 in women. Onset occurred most often between the age of 65–74 years in men and 55–64 years in women. The ALS incidence tended to increase over the period 1995–2009. The mean age at onset was 61.7 years with no difference based on gender, varying significantly from 59.9 years in 1995–1999 to 63.9 years in 2005–2009. On December 31, 2009, the ALS crude prevalence was 10.8 per 100,000 (95 % CIs: 8.6, 13.1), 13.8 in men and 8.0 in women, whereas it was 6.3 per 100,000 (95 % CIs: 4.1, 8.6) on December 31, 2004 (M:F ratio of 0.95). Mean survival from onset was 37.0 months, with no difference based on gender, and a tendency to decrease during the period 1995–2009, in relation to type and age of onset. The population-based incidence and prevalence data of ALS in Sardinians indicate an increase of the disease occurrence over the past 40 years, providing support for a population-specific variant of ALS in Sardinia.
- Open Access
- 23 May 2012
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 18 (2_suppl) , 5-6
The Treatment experience, burden, and unmet needs (TRIBUNE) study – measuring the socioeconomic consequences of Multiple Sclerosis
- 23 May 2012
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 18 (2_suppl) , 5-6
Open AccessThe Treatment experience, burden, and unmet needs (TRIBUNE) study – measuring the socioeconomic consequences of Multiple Sclerosis
- 1 January 2009
- Published by Touch Medical Media, Ltd. in European Neurological Review
- Vol. 4 (2)
Cost of Brain Disorders in Italy – A Review
Brain disorders represent 35% of the total disease burden in Europe and 37% of the total disease burden in European regions with very low child mortality and low adult mortality; the latter group includes Italy. The negative socioeconomic impact of this burden is reflected in two fundamental issues: consumption of resources and state of health. In recent years, the European Brain Council (EBC), a co-ordinating council formed by European organisations and patient associations in neurological disorders, has encouraged and supported projects aimed at analysing the socioeconomic burden of brain disorders in Europe. Within the EBC, the pan-European study on Cost of Disorders of the Brain in Europe (CDBE) aimed at reporting the best possible estimates of the societal cost of 12 brain disorders (addiction, affective disorders, anxiety disorders, tumours, dementia, epilepsy, migraine and other headaches, multiple sclerosis, Parkinson's disease, psychotic disorders, stroke and trauma) based on the existing literature, using an ad hoc cost model. The aggregated results for Italy from the CDBE study are reviewed in this paper.
- 1 January 2009
- Published by Touch Medical Media, Ltd. in European Neurological Review
- Vol. 4 (2)
Cost of Brain Disorders in Italy – A Review
Brain disorders represent 35% of the total disease burden in Europe and 37% of the total disease burden in European regions with very low child mortality and low adult mortality; the latter group includes Italy. The negative socioeconomic impact of this burden is reflected in two fundamental issues: consumption of resources and state of health. In recent years, the European Brain Council (EBC), a co-ordinating council formed by European organisations and patient associations in neurological disorders, has encouraged and supported projects aimed at analysing the socioeconomic burden of brain disorders in Europe. Within the EBC, the pan-European study on Cost of Disorders of the Brain in Europe (CDBE) aimed at reporting the best possible estimates of the societal cost of 12 brain disorders (addiction, affective disorders, anxiety disorders, tumours, dementia, epilepsy, migraine and other headaches, multiple sclerosis, Parkinson's disease, psychotic disorders, stroke and trauma) based on the existing literature, using an ad hoc cost model. The aggregated results for Italy from the CDBE study are reviewed in this paper.
- 1 April 2008
- Published by Springer Nature in Neurological Sciences
- Vol. 29 (2) , 99-107
Cost of disorders of the brain in Italy
- 1 April 2008
- Published by Springer Nature in Neurological Sciences
- Vol. 29 (2) , 99-107
Cost of disorders of the brain in Italy
- 20 February 2008
- Published by Springer Nature in Journal of Neurology
- Vol. 255 (2) , 157-162
Self-perceived physical functioning and health status among fully ambulatory multiple sclerosis patients
We investigated the self-perceived health status among multiple sclerosis (MS) patients with no or mild disability according to the Expanded Disability Status Scale (EDSS) and the impact of self-rated physical functioning. A sample of fully ambulatory (EDSS ≤ 3.5) consecutive patients with MS was included after screening for major cognitive impairment. The EDSS was used to measure nervous system signs or disability, and the self-rated health status was assessed using the SF-36 Health Survey. The normative SF-36 data for the general population of Italy were used for comparison. The 197 MS patients analyzed (150 women and 47 men) had significantly lower mean SF-36 scores than the general population, except for bodily pain. The scores did not differ significantly by gender. The same analysis performed on a subsample of 105 patients (79 women and 26 men) with minimal disability in one functional system (EDSS ≤ 2.0) yielded similar results. EDSS was weakly correlated with the physical functioning subscale and explained only 2% of the variance in the physical functioning subscale. The regression of the physical functioning subscale on the other seven SF-36 subscales was significantly lower among MS patients than in the general population for all subscales, except for role limitation due to physical health problems and social functioning. Neither disease course nor duration correlated significantly with SF-36 subscales. The SF-36 physical functioning subscale seemed to indicate physical functioning more sensitively than EDSS. These findings should encourage the implementation of specific strategies aimed at improving the quality of the self-perceived health status already in the early disease stage.
- 20 February 2008
- Published by Springer Nature in Journal of Neurology
- Vol. 255 (2) , 157-162
Self-perceived physical functioning and health status among fully ambulatory multiple sclerosis patients
We investigated the self-perceived health status among multiple sclerosis (MS) patients with no or mild disability according to the Expanded Disability Status Scale (EDSS) and the impact of self-rated physical functioning. A sample of fully ambulatory (EDSS ≤ 3.5) consecutive patients with MS was included after screening for major cognitive impairment. The EDSS was used to measure nervous system signs or disability, and the self-rated health status was assessed using the SF-36 Health Survey. The normative SF-36 data for the general population of Italy were used for comparison. The 197 MS patients analyzed (150 women and 47 men) had significantly lower mean SF-36 scores than the general population, except for bodily pain. The scores did not differ significantly by gender. The same analysis performed on a subsample of 105 patients (79 women and 26 men) with minimal disability in one functional system (EDSS ≤ 2.0) yielded similar results. EDSS was weakly correlated with the physical functioning subscale and explained only 2% of the variance in the physical functioning subscale. The regression of the physical functioning subscale on the other seven SF-36 subscales was significantly lower among MS patients than in the general population for all subscales, except for role limitation due to physical health problems and social functioning. Neither disease course nor duration correlated significantly with SF-36 subscales. The SF-36 physical functioning subscale seemed to indicate physical functioning more sensitively than EDSS. These findings should encourage the implementation of specific strategies aimed at improving the quality of the self-perceived health status already in the early disease stage.
- Open Access
Estimating the Cost of Epilepsy in Europe: A Review with Economic Modeling
Summary: Purpose:Based on available epidemiologic, health economic, and international population statistics literature, the cost of epilepsy in Europe was estimated.Methods:Europe was defined as the 25 European Union member countries, Iceland, Norway, and Switzerland. Guidelines for epidemiological studies on epilepsy were used for a case definition. A bottom‐up prevalence‐based cost‐of‐illness approach, the societal perspective for including the cost items, and the human capital approach as valuation principle for indirect costs were used. The cost estimates were based on selected studies with common methodology and valuation principles.Results:The estimated prevalence of epilepsy in Europe in 2004 was 4.3–7.8 per 1,000. The estimated total cost of the disease in Europe was €15.5 billion in 2004, indirect cost being the single most dominant cost category (€8.6 billion). Direct health care costs were €2.8 billion, outpatient care comprising the largest part (€1.3 billion). Direct nonmedical cost was €4.2 billion. That of antiepileptic drugs was €400 million. The total cost per case was €2,000–11,500 and the estimated cost per European inhabitant was €33.Conclusions:Epilepsy is a relevant socioeconomic burden at individual, family, health services, and societal level in Europe. The greater proportion of such burden is outside the formal health care sector, antiepileptic drugs representing a smaller proportion. Lack of economic data from several European countries and other methodological limitations make this report an initial estimate of the cost of epilepsy in Europe. Prospective incidence cost‐of‐illness studies from well‐defined populations and common methodology are encouraged.
Open AccessEstimating the Cost of Epilepsy in Europe: A Review with Economic Modeling
Summary: Purpose:Based on available epidemiologic, health economic, and international population statistics literature, the cost of epilepsy in Europe was estimated.Methods:Europe was defined as the 25 European Union member countries, Iceland, Norway, and Switzerland. Guidelines for epidemiological studies on epilepsy were used for a case definition. A bottom‐up prevalence‐based cost‐of‐illness approach, the societal perspective for including the cost items, and the human capital approach as valuation principle for indirect costs were used. The cost estimates were based on selected studies with common methodology and valuation principles.Results:The estimated prevalence of epilepsy in Europe in 2004 was 4.3–7.8 per 1,000. The estimated total cost of the disease in Europe was €15.5 billion in 2004, indirect cost being the single most dominant cost category (€8.6 billion). Direct health care costs were €2.8 billion, outpatient care comprising the largest part (€1.3 billion). Direct nonmedical cost was €4.2 billion. That of antiepileptic drugs was €400 million. The total cost per case was €2,000–11,500 and the estimated cost per European inhabitant was €33.Conclusions:Epilepsy is a relevant socioeconomic burden at individual, family, health services, and societal level in Europe. The greater proportion of such burden is outside the formal health care sector, antiepileptic drugs representing a smaller proportion. Lack of economic data from several European countries and other methodological limitations make this report an initial estimate of the cost of epilepsy in Europe. Prospective incidence cost‐of‐illness studies from well‐defined populations and common methodology are encouraged.